BioSpace News Archive

Most people don’t know that asking questions can help with an application. Here are some unique questions for interviewer that you should remember to ask next time.

When dealing with a large group of people, the possibility of handling a disgruntled employee is very likely. Here’s how you can handle them efficiently.

Nicox SA, an international ophthalmology company, announced that it has amended its March 2019 license agreement with Ocumension Therapeutics, under which Ocumension has exclusive rights to develop and commercialize ZERVIATE®, 0.24% in the Chinese and the majority of South East Asian markets.

Skanska has signed a contract with the New York City Economic Development Corporation to construct a new municipal health lab in Harlem, New York, USA.

SINOMED, a leading international medical device company, announced that they have teamed up with the National University of Ireland Galway to conduct a clinical trial for a new assessment method for stenting.

Everest Medicines announced that Spero Therapeutics, Inc., a licensing partner of Everest Medicines, entered into a regional licensing agreement with Pfizer Inc. for SPR206, Spero’s intravenously -administered next-generation polymyxin product candidate being developed to treat serious multi-drug resistant Gram-negative infections in the hospital setting.

Octapharma announced that new clinical and scientific findings encompassing their Haematology portfolio, including Nuwiq®, wilate®, octanate® and octanine®F, will be presented at the upcoming International Society on Thrombosis and Haemostasis Virtual Congress, taking place on July 17–21, 2021.

HUTCHMED Limited has initiated a Phase I study of HMPL-295, its investigative and highly selective oral inhibitor of ERK, which is a downstream component of the RAS-MAPK1 pathway signaling cascade.

Ultimovacs ASA, a clinical stage leader in immune stimulatory vaccines for cancer, announced the publication of a review of telomerase-based therapeutic cancer vaccines including the Company’s universal cancer vaccine, UV1.

GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that the French Competent Authority, the National Agency for Medicines and Health Products Safety, granted a Cohort Temporary Authorization for Use for LUMEVOQ® in the treatment of Leber Hereditary Optic Neuropathy caused by a mutated ND4 gene.